Patient

Respiratory Syncytial Virus (RSV): A Disease of All Ages

RSV is a common cause of acute respiratory illness in infants, young children, older adults, and adults with certain comorbidities1

RSV is a common and contagious virus causing repeated infections throughout life, and is associated with significant clinical and economic burden in older adults and adults with certain underlying comorbidities2-4

Virus, RSV

Most children have had an RSV infection by two years of age.5 The protective immunity after RSV natural infection is not long-lasting, and re-infection occurs throughout life.2,3

Medical, Heartbeat

In adults, RSV infection typically results in mild, cold-like symptoms; however, it may lead to serious complications, hospitalization and death.4

Patient, RSV

Older adults, individuals with comorbidities, and those with weakened immune systems are at increased risk of severe illness from RSV infection4

Estimated annual burden of RSV infection among older adults aged ≥65 years in the US:5

Patient

3-7% of older adults develop RSV in a typical year, resulting in ~2.2 million symptomatic infections6,7

Stethoscope, Patient, RSV

~177,000 hospitalizations due to RSV infection6,7

Medical, RSV

~14,000 deaths due to RSV infection6,7*

*Based on 8% death rate for hospitalized patients with RSV infection7

Learn more about RSV disease and its burden in adults:

RSV, Virus

RSV Disease Overview

RSV is a contagious respiratory virus that can lead to serious complications

LEARN MORE

RSV, Virus

Risk Factors and Clinical Burden of RSV in Older Adults

Older adults and adults with underlying conditions are at increased risk of severe illness due to RSV infection

LEARN MORE

RSV, Virus

RSV Diagnosis, Prevention, & Management

Testing for RSV is key for diagnosis. There currently is no specific treatment or prevention for RSV disease in adults

LEARN MORE

Abbreviation

RSV, respiratory syncytial virus

References

  1. CDC, 2020. RSV -For Healthcare Providers. https://www.cdc.gov/rsv/clinical/index.html. Accessed September 2022.
  2. Graham BS. Immunol Rev 2011;239:149–166.
  3. Anderson LJ et al. Vaccine 2013;31S:B209–B215.
  4. CDC, 2020. RSV in older adults and adults with chronic medical conditions. https://www.cdc.gov/rsv/high-risk/older-adults.html. Accessed August 2022.
  5. CDC, 2020. RSV in infants and young children. https://www.cdc.gov/rsv/high-risk/infants-young-children.html. Accessed August 2022.
  6. June 2022 ACIP presentation on "RSV in adults". Available at: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-06-22-23/04-RSV-Havers-508.pdf. Accessed January 2023.
  7. Falsey AR et al. N Engl J Med 2005;352:1749–1759.

Material supplied by the above-country business unit to LOCs for localisation must be subject to local Medical and/or Regulatory review and approval prior to use and/or external distribution.

LOCs to insert local adverse events reporting procedure.

©2023 GSK group of companies or its licensor. GlaxoSmithKline Biologicals SA. Rixensart, Belgium.

NX-GBL-RSA-WCNT-220001 | January 2023